Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology

Home Page
About
Submit A Journal
Submit A Conference
Submit Paper/Book
- Submit a Preprint
- Submit a Book
Contact

International Journal of Chemistry and Technology
Volume:3 Issue:2
Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology

Recombinant human G-CSF production as a protein based drug candidate for hematology and oncology

Authors : Yasemin BOZKURT, Sema BİLGİN, Seçil ERDEN, İsmail Furkan TURAN, İsa GÖKÇE

Pages : 92-100

Doi:10.32571/ijct.600180

View : 89 | Download : 10

Publication Date : 2019-12-31

Article Type : Research Paper

Abstract :The human granulocyte colony stimulating factor insert ignore into journalissuearticles values(hG-CSF); is a member of the CSF family. The first purpose of this study was production of recombinant human G-CSF insert ignore into journalissuearticles values(rhG-CSF); which is an important therapeutic protein for angiogenesis based clinical applicaitons. rhG-CSF was produced as inclusion body in the Escherichia coli strain BL21 insert ignore into journalissuearticles values(DE3); pLysE with pTOLT vector system. The rhG-CSF was purified by Ni-NTA agarose afinity chromatography and characterized with SDS-PAGE analysis. The effects of this therapeutic protein on cell viability was measured by MTT assay. Additionally, angiogenic potential of produced rhG-CSF was investigated via HUVEC cell line by in vitro scratch assay. As a result, the purified protein induced cell proliferation and the EC50 value of protein based drug candidate was 0.051 mM. Additionally, it was determined that the migration ability of the HUVECs was promoted by rhG-CSF in a concentration-dependent manner by in vitro scratch assay.
Keywords : Granulocyte colony stimulating factor, recombinant proteins, angiogenesis, cell proliferation

ORIGINAL ARTICLE URL

* There may have been changes in the journal, article,conference, book, preprint etc. informations. Therefore, it would be appropriate to follow the information on the official page of the source. The information here is shared for informational purposes. IAD is not responsible for incorrect or missing information.